Enisamium reduces influenza virus shedding and improves patient recovery by inhibiting viral RNA polymerase activity

Competing Interest Statement

The University of Cambridge received consulting fees for the experiments and analyses performed. The Icahn School of Medicine at Mount Sinai, New York, NY received consulting fees for the experiments and analyses performed. The University of Wisconsin - Madison received consulting fees for work performed for this study by Andrew Mehle. Norbert Gmeinwieser received personal fees from Pharmalog Institut fuer klinische Forschung GmbH, subcontracted service CRO for writing the manuscript. Holger Stammer received personal fees from Pharmalog Institut fuer klinische Forschung GmbH, subcontracted service CRO for review of the manuscript. Jens Milde received personal fees from Pharmalog Institut fuer klinische Forschung GmbH, subcontracted service CRO for review of the manuscript. Lutz Mueller received personal fees from Dr. Regenold GmbH, subcontracted consultant for product development and for review of the manuscript. Victor Margitich received personal fees from JSC Farmak, sponsor of the clinical trials and funding of the medical writing, for planning and coordinating the experiments and review of the manuscript.

Clinical Trial

Data is available from on ClincalTrials.gov under NCT04682444. Study was also registered under EudraCT No. 2009-015382-32

Funding Statement

The clinical trial and medical writing of the publication manuscript was funded by JSC Farmak. A.J.W. te Velthuis is supported by joint Wellcome Trust and Royal Society grant 206579/Z/17/Z and the National Institutes of Health grant R21AI147172. A. Mehle holds an Investigators in the Pathogenesis of Infectious Disease Award from the Burroughs Wellcome Fund. The University of Cambridge received consulting fees for the experiments and analyses performed. The Icahn School of Medicine at Mount Sinai, New York, NY received consulting fees for the experiments and analyses performed. The University of Wisconsin - Madison received consulting fees for work performed. Norbert Gmeinwieser received personal fees from Pharmalog Institut fuer klinische Forschung GmbH, subcontracted service CRO for writing the manuscript. Holger Stammer received personal fees from Pharmalog Institut fuer klinische Forschung GmbH, subcontracted service CRO for review of the manuscript. Jens Milde received personal fees from Pharmalog Institut fuer klinische Forschung GmbH, subcontracted service CRO for review of the manuscript. Lutz Mueller received personal fees from Dr. Regenold GmbH, subcontracted consultant for product development and for review of the manuscript. Victor Margitich received personal fees from JSC Farmak, sponsor of the clinical trial and funding of the medical writing, for planning and coordinating the experiments and review of the manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Study 1 was approved by the Ethics Commission of the Research Institute of Influenza of the NWB RAMS (Extract of report No 28 of 09 April 2009) after review of the clinical trial protocol, Investigator's Brochure, patient information with informed consent, case report forms, insurance policy, and the qualifications of the investigator. Study 2 was approved by the Ethics Commission of the Medical University Vienna and the General Hospital Vienna (reference no. 868/2009, dated 27 November 2009) after review of the clinical trial protocol, Investigator's Brochure, patient information with informed consent, insurance policy, and qualification of the investigator.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes